Kittleson et al., 2016 - Google Patents
Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart TransplantationKittleson et al., 2016
View PDF- Document ID
- 2981121268801837438
- Author
- Kittleson M
- Patel J
- Czer L
- Aintablian T
- Rodriguez G
- Velleca A
- Kearney B
- Chang D
- Hamilton M
- Esmailian F
- Zhang X
- Reinsmoen N
- Kobashigawa J
- Publication year
- Publication venue
- The Journal of Heart and Lung Transplantation
External Links
Snippet
Purpose Everolimus and sirolimus are proliferation signal inhibitors (PSI) reported to decrease incidence and progression of transplant coronary artery disease, incidence of cardiac rejection, and development of de novo circulating antibodies (Abs) in the 1st year …
- 230000035755 proliferation 0 title abstract description 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Von Kobbe | Targeting senescent cells: approaches, opportunities, challenges | |
| Eisen et al. | Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial | |
| Coenen et al. | Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells | |
| Gui et al. | mTOR signaling in kidney diseases | |
| Tuuminen et al. | Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection | |
| Yaich et al. | Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases | |
| Klintmalm et al. | The role of mammalian target of rapamycin inhibitors in the management of post‐transplant malignancy | |
| Nair et al. | Current and future challenges in therapy for antibody-mediated rejection | |
| Liu et al. | Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells | |
| Preidl et al. | Clopidogrel reduces post‐transplant obliterative bronchiolitis | |
| Kittleson et al. | Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation | |
| Sancho et al. | Effect of overweight on kidney transplantation outcome | |
| Liu et al. | Phosphoinositide 3-kinase inhibitor LY294002 ameliorates the severity of myosin-induced myocarditis in mice | |
| Chuang et al. | Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression | |
| Song et al. | Recipient efficacy and safety of kidney transplantation from older living donor: consideration for using older kidney as a solution to the shortage of organs | |
| Patel et al. | Does the Development of Donor Specific Antibody after Heart Transplantation Depend on the Presence or Absence of Corticosteroids as Maintenance Therapy? | |
| Seth et al. | Risk for delayed graft function in deceased donor renal transplant patients: a single-center experience from North India | |
| Boletis et al. | Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression | |
| Watada et al. | Effect of sarpogrelate hydrochloride, a 5-hydroxytryptamine2 receptor antagonist, on allograft arteriosclerosis after aortic transplantation in rats | |
| Davids et al. | The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia | |
| Stepanenko et al. | 182 Impact of Surgical Approach on Adverse Neurological Events: Single-Center Experience with HeartWare HVAD Implanted Via Left Lateral Thoracotomy | |
| Tan et al. | IMMUNOFLUORESCENCE DETECTION OF COMPLEMENT ACTIVATION PRODUCTS C4D AND C3D CORRELATES WITH CARDIAC ALLOGRAFT DYSFUNCTION AND DONOR SPECIFIC ANTIBODIES IN HUMAN HEART TRANSPLANTS: 689 | |
| Rodriguez et al. | MICROARRAY ANALYSIS SHOWS THAT NEUROPILIN2, ESDN, VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS 1 AND 2 (VEGFR1 AND 2) ARE DIFFERENTIALLY EXPRESSED IN PROLIFERATIVE CORONARY LESIONS FROM ATHEROSCLEROTIC AND TRANSPLANT VASCULOPATHY HUMAN ARTERIES: 688 | |
| Ramanan et al. | Bloodstream Infections (BSI) in Patients Undergoing Liver Transplantation (LT) for Hilar Cholangiocarcinoma (CCA).: Abstract# A389 | |
| Novotny et al. | Case Report Deceased Donor Renal Transplantation Combined with Bilateral Nephrectomy in a Patient with Tuberous Sclerosis and Renal Failure |